AI-generated analysis. Always verify with the original filing.
Arbutus Biopharma Corporation announced fourth quarter and year-end 2025 financial results, reporting net loss of $33.5 million or $0.17 per share, revenue of $14.1 million, and cash of $91.5 million as of December 31, 2025. Highlights include a $2.25 billion Moderna settlement and two additional functional cures in imdusiran Phase 2a trials, bolstering financial position and clinical progress.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 23, 2026, Arbutus Biopharma Corporation issued a press release announcing its financial results for th
. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 23, 2026 104 Cover Page Interactive Data File (embe
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $14.10 | GAAP |
| Loss from Operations | $-38.20 | GAAP |
| Net Loss | $-33.50 | GAAP |
| Net Loss per Common Share Basic and Diluted | $-0.17 | GAAP |